Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
148 results about "Dextran sulfate" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Dextran sulfate contains approximately 17% sulfur which is equivalent to approximately 2.3 sulfate groups per glucosyl residue. Dextran is a polymer of anhydroglucose. It is composed of approximately 95% alpha-D-(166) linkages.
Gel composition for cellular adhesion inhibition
InactiveUS20070031498A1Avoid stickingInhibiting adhesion of cellPowder deliveryBiocideAdhesion processPolyethylene glycol
The invention includes compositions for inhibiting cellular adhesion, methods of preparation of such compositions, and methods for preventing cell adhesion at a surgical site comprising application of such compositions. The compositions generally comprise a cellular adhesion inhibitory agent, such as dextran sulfate, and a crosslinked hydrogel matrix, preferentially physically entrapping the adhesion inhibitory agent. The hydrogel matrix can include a first gel component, such as an electrophilically functionalized polyethylene glycol polymer, and at least one additional gel component, preferably nucleophilically functionalized, and preferentially selected from the group consisting of polyethylene glycol polymers, polypeptides, and polysaccharides. The compositions are useful for delivering the cellular adhesion inhibitory agent to a site in need of adhesion inhibition and providing either immediate or metered delivery of the inhibitory agent.
Owner:TRIAD
Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
Owner:TRIAD
Hepatitis B virus binding proteins and uses thereof
An isolated nucleic acid, a recombinant protein encoded thereby and uses thereof. The isolated nucleic acid including (a) a polynucleotide at least 60% identical to SEQ ID NOs:1, 3, 5 or portions thereof as determined using the Bestfit procedure of the DNA sequence analysis software package developed by the Genetic Computer Group (GCG) at the university of Wisconsin (gap creation penalty-50, gap extension penalty-3); (b) a polynucleotide encoding a polypeptide being at least 60 homologous with SEQ ID NOs:2, 4, 6 or portions thereof as determined using the Bestfit procedure of the DNA sequence analysis software package developed by the Genetic Computer Group (GCG) at the university of Wisconsin (gap creation penalty-50, gap extension penalty-3); or (c) a polynucleotide hybridizable with SEQ ID NOs:1, 3, 5 or portions thereof at 68° C. in 6xSSC, 1% SDS, 5xDenharts, 10% dextran sulfate, 100 mug / ml salmon sperm DNA, and 32p labeled probe and wash at 68° C. with 3xSSC and 0.1% SDS.
Owner:YEDA RES & DEV CO LTD
Method for inhibition of bone growth by anionic polymers
InactiveUS6020326AInhibit bone growthPrevent invasionAntibacterial agentsOrganic active ingredientsCell invasionFibrosis
The present invention relates to the discovery that biocompatible anionic polymers can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that anionic polymers effectively inhibit invasion of cells associated with detrimental healing processes, and in particular, that the effectiveness of an anionic polymer at inhibiting cell invasion correlates with the anionic charge density of the polymer. Thus the present invention provides a large number of materials for use in methods of inhibiting fibrosis and fibroblast invasion. Anionic polymers for use in the invention include but are not limited to natural proteoglycans, and the glycosaminoglycan moieties of proteoglycans. Additionally, anionic carbohydrates and other anionic polymers may be used. The anionic polymers dextran sulfate and pentosan polysulfate are preferred. In a more preferred embodiment, dextran sulfate, in which the sulfur content is greater than about 10% by weight, may be used. In a more preferred embodiment, the average molecular weight is about 40,000 to 500,000 Daltons. The present invention provides compositions and methods to inhibit fibrosis and scarring associated with surgery. The invention further provides compositions and methods to inhibit glial cell invasion, detrimental bone growth and neurite outgrowth. In a preferred embodiment, the inhibitory compositions further comprise an adhesive protein.
Owner:TRIAD
Cross-linked polysaccharide drug carrier
InactiveUS6953784B2High biodegradation rateControl releasePowder deliveryOrganic active ingredientsCross-linkDextran
A carrier and a method for preparing it are provided for use in the delivery of therapeutic agents. A polysaccharide is reacted with an oxidizing agent to open sugar rings on the polysaccharide to form aldehyde groups. The aldehyde groups are reacted to form covalent oxime linkages with a second polysaccharide and each of the first and second polysaccharide is selected from the group consisting of hyaluronic acid, dextran, dextran sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparan, heparan sulfate and alginate.
Owner:DEPUY SPINE INC (US)
Method and kit for separating exosome
PendingCN106399250AHigh yieldIncrease productionArtificial cell constructsSkeletal/connective tissue cellsInorganic saltsHydrophilic polymers
The invention discloses a method and kit for separating exosome. The invention provides a reagent. The reagent is an aqueous solution of a hydrophilic polymer or a salt solution, wherein the hydrophilic polymer is PEG, dextran sulfate, or PVP, or a composition thereof. Experimental results prove that the exosome can be successfully separated by using a plurality of hydrophilic polymers; and the yield of separated exosome can be increased by using a composition of a hydrophilic polymer and an inorganic salt.
Owner:广州锐博生物技术有限公司
Methods and compositions of inhibiting complement and cellular activation with dextran sulfate
InactiveUS20100087393A1Minimized and reduced hemorrhagic propertyHigh selectivityBiocideOrganic active ingredientsBiological activationCell biology
A method of inhibiting the adverse effects of complement pathway, activation products in a subject comprising administering to the subject an amount of Dextran Sulfate effective to inhibit formation of alternative complement pathway activation product.
Owner:NOVELMED THERAPEUTICS
Kit and method for preparing exosomes in serum or plasma
ActiveCN108918228AConcentrated particle size distributionSimple purification processPreparing sample for investigationHydrophilic polymersPolyethylene glycol
The invention discloses a kit and method for preparing exosomes in serum or plasma. The kit comprises an exosome extracting reagent, wherein the exosome extracting reagent is a hydrophilic polymer ora solution of the hydrophilic polymer; the hydrophilic polymer comprises one or a combination of PEG (Poly Ethylene Glycol), dextran sulfate and PVP (Poly Vinyl Pyrrolidone); the molecular weight of the PEG is 20000-1200000 Daltons; the molecular weight of the dextran sulfate is 5000 to 20000 Daltons; and the molecular weight of the PVP is 10000 or 40000-700000 Daltons. The particle size distribution of the exosomes obtained by utilizing the kit is more concentrated; and according to the method for preparing the exosomes, which is provided by the invention, the step of purifying the exosomes is also optimized, so that the exosomes have less impurities and higher purity.
Owner:BEIJING TRANSGEN BIOTECH CO LTD
Nanoparticles for Imaging Atherosclerotic Plaque
InactiveUS20080206150A1Reduce contrastStrong specificityUltrasonic/sonic/infrasonic diagnosticsBiocideDiseaseScavenger
Atherosclerosis is an inflammatory disease of the arterial walls and represents a significant health problem in developed nations. Described is a targeted Magnetic Resonance Imaging (MRI) contrast agent for in vivo imaging of early stage atherosclerosis. Early plaque development is characterized by the influx of macrophages, which express a class of surface receptors known collectively as the scavenger receptors (SR). The macrophage scavenger receptor class A (SRA) is highly expressed during early atherosclerosis. The macrophage SRA therefore presents itself as an ideal target for labeling of lesion formation. By coupling a known ligand for the scavenger receptor, dextran sulfate, to a MRI contrast agent, early plaque formation can be detected in vivo. Targeted MR contrast agents offer a unique opportunity to visualize early plaque development in vivo with high sensitivity and resolution, allowing or early diagnosis and treatment of atherosclerosis.
Owner:RGT UNIV OF CALIFORNIA
Stabilized enzyme compositions
ActiveUS20100215711A1Reduce formationReduce microbial growthAntibacterial agentsPeptide/protein ingredientsMedical deviceMedical treatment
A medical device includes a base material having an immobilized fibrinolytic enzyme and dextran sulfate. The dextran sulfate has a molecular weight that is less than 40 kilo dalton (kDa). The medical device is formed from at least a base material. A fibrinolytic enzyme is immobilized on the base material. The fibrinolytic enzyme is stabilized with a dextran sulfate having a molecular weight of less than 40 (kDa).
Owner:TELEFLEX MEDICAL INC +1
Method for virus detection by surface plasma resonance technology and chip used in the same
InactiveCN101464456AScattering properties measurementsBiological testingHuman papillomavirusPlasma resonance
The invention provides a method for detecting viruses through a surface plasma resonance technology (SPR), which comprises the steps as follows: a sample to be detected is mixed with a buffer solution including an SSPE solution and a dextran sulfate solution, and the formed mixture contains a solution of 1-10 multiplied by SSPE and 0.5 to 10 percent of the dextran sulfate solution; the mixture isled to flow through an SPR biosensor chip; a probe special to the viruses is connected with the chip; the signal difference of corresponding flowing pools before and after the mixture flows through the chip is measured through the SPR; and the signal difference and the signal difference of a comparison flowing pool are compared so as to determine whether the viruses exist. The method is especially suitable for detecting human papillomavirus (HPV). In addition, the invention further provides the SPR biosensor chip used in the method.
Owner:BEIJING GP MEDICAL TECH
Determination kit for lipoprotein (a)
ActiveCN109541241AExtended storage timeImprove accuracyBiological testingPolyethylene glycolLatex particle
The invention provides a determination kit for lipoprotein (a), and relates to the technical field of medical biological detection. The kit comprises reagents R1 and R2, a calibration product and a quality control product, wherein the reagent R1 comprises trihytdroxy methyl-aminomethane, sodium chloride, polyethylene glycol-6000, biological preservative and surfactant, and the reagent R2 comprisestrihytdroxy methyl-aminomethane, goat anti-human lipoprotein (a) antibody latex particles, dibutyl methyl methylbenzene, glycine, dextran sulfate, biological preservative and surfactant. The kit adopts a latex turbidimetric inhibition immunoassay, latex reagent with a mixed particle size is used, a fully automatic biochemical analyser can be used to simultaneously detect a great quantity of samples, so that linearity is good, detection sensitivity, accuracy and accuracy can be improved, detection time is shortened, operation is simple, economic cost is low, and storage time is long.
Owner:浙江夸克生物科技有限公司
Serum-free mammalian cell culture medium, and uses thereof
InactiveUS20090280532A1Improve expression levelIncrease productionBiocideInorganic active ingredientsMammalCell culture media
Owner:LIFE TECH CORP
Microfluidic system and coating method therefor
InactiveUS20080056947A1Faster filling timeResists contaminationVacuum evaporation coatingPretreated surfacesALLYL SUCROSEPolyacrylic acid
A microfluidic system having a microchannel for the capillary transport of a liquid, in particular a body fluid for analytical purposes. The microchannel is provided with a surface coating comprising at least one hydrophilic substance selected from the group consisting of polyacrylic acid, polyacrylate, dextran sulfate and chondroitin sulfate. The invention also concerns a coating method that is suitable for this.
Owner:ROCHE DIABETES CARE INC
Application of dextran sulfate in preparing medicament for treating hepatic fibrosis
InactiveCN102973593ARelieve symptomsStrong inhibition of activationOrganic active ingredientsRespiratory disorderPharmaceutical drugCurative effect
The invention discloses novel application of dextran sulfate in preparing a medicament for treating hepatic fibrosis. The medicament can be used for inhibiting inflammatory reaction in hepatic fibrosis attaching process, so that attack or symptom worsening of hepatic fibrosis can be inhibited. Dextran sulfate has good curative effect in a carbon tetrachloride induced animal model; and the medicaments used in the application can be easily acquired, low in price and stable in properties, are convenient to store and transport, and have wide application prospect.
Owner:合肥博太医药生物技术发展有限公司
Determination reagent of total bile acid
The invention relates to a determination reagent of a total bile acid. The reagent comprises two components, wherein the reagent 1 comprises a phosphate buffer, Thio-NAD (Nicotinamide Adenine Dinucleotide), Emulgen B-66 CTAB (Cetyltrimethyl Ammonium Bromide), NaCl, 2-hydroxypyridine-N-oxide; the reagent 2 comprises a glycinate buffer, dextran sulfate, EGTA (Ethylene Glycol Tetraacetic Acid), 3 alpha-HSD (Hydrogen Sterol Dehydrogenase), Emulgen B-66, NADH (Nicotinamide-adenine Dinucleotide Acid), and 2-hydroxypyridine-N-oxide. As the combination of the cation surfactant and the nonionic surfactant Emulgen B-66 is added, the interference of bilirubin can be effectively eliminated; the selected stabilizer is added in the product, so that the reagent can be stored for one year at 2-8 DEG C without influence on the properties; the substrate concentration and the ion strength can be adjusted to enable the recovery rate of the reagent to be more than 98%. The determination reagent disclosed by the invention has the advantages of high accuracy in determined results, strong anti-interference performance, good stability and the like.
Owner:武汉利弘生物科技有限责任公司
Cohesive coprecipitates of sulfated polysaccharide and fibrillar protein and use thereof
InactiveUS20060110426A1Improve the environmentEasy to useBiocideAerosol deliverySulfated polysaccharidesBiopolymer
The present invention concerns cohesive biopolymer gels comprising coprecipitates of sulfated polysaccharides and fibrillar proteins, exemplified by coprecipitates of dextran sulfate and gelatin, useful for clinical applications including as implants for tissue engineering as well as in biotechnology. The cohesive biopolymer gels according to the present invention may be used clinically either per se or as a scaffold for a cell-bearing implant, as a depot for sustained release of bioactive agents, or for research and biotechnology.
Owner:NVR LABS
Bone-pathobolism treating agent
InactiveUS6919312B2High activityImprove actionBiocideOrganic active ingredientsTreatment effectIncreased calcium
A novel bone-pathobolism treating agent is provided. A bone-pathobolism treating agent comprising at least one substance selected from the group consisting of osteoclastogenesis inhibitory factor (OCIF), its homologs, and its variants, and a polysaccharide or its derivatives. As the polysaccharide or its derivatives, heparin, dextran sulfate and the like can be used. A bone-pathobolism treating agent is provided which has excellent therapeutic effect on bone-pathobolism such as osteoporosis, hypercalcemia, or chronic articular rheumatism and persistance of the activity. The agent is useful as a medicine.
Owner:SANKYO CO LTD
Horseradish peroxidase black developer, and preparation method and application thereof
ActiveCN103323448AColor difference visual effect is goodEasy to judge the resultMaterial analysis by observing effect on chemical indicatorBetainePeroxidase
The invention relates to a horseradish peroxidase black developer, and a preparation method and an application thereof, and belongs to the technical field of biology. The raw materials of the horseradish peroxidase black developer comprise: 4-CN, DAB, ammonium nickel sulfate, cobaltous chloride, imidazole, polyoxyethylene octyl phenyl ether, boric acid, MgCl2, MnCl2, sodium nitroferricyanide, betaine, gelatin, tetrahydrofuran, acetone, dextran sulfate, 1*TBS and H2O2. The horseradish peroxidase black developer is obtained by uniformly mixing a certain amount of the raw materials. By using the horseradish peroxidase black developer, the color development of a horseradish peroxidase has the advantages of high sensitivity of DAB and good color-difference visual sense effect of 4-CN at the same time, and the color substance is a black deposition with a strong background contrast, and therefore the result determine is convenient.
Owner:WENZHOU MEDICAL UNIV
Low-density lipoprotein adsorbent and preparation method thereof
ActiveCN109092263AHigh specific adsorption levelImprove adsorption capacityOther chemical processesOther blood circulation devicesPorositySpecific adsorption
The invention discloses a low-density lipoprotein adsorbent and an adsorption column. Agarose gel microspheres of a specific particle size and a specific porosity are adopted as a carrier, are modified by using an epoxy method and are coupled with dextran sulfate ligand molecules of a specific molecular weight. The adsorbent prepared by using the method has a high specific adsorption level and good hemocyte permeability on one hand, on the other hand, has a low non-specific adsorption level, and has excellent clinical application values.
Owner:WUHAN RUIFA MEDICAL DEVICES CO LTD
Cellulose sulfate and other sulfated polysaccharides to prevent and treat papilloma virus infection and other infections
Owner:RUSH UNIV MEDICAL CENT +1
Method for biologically removing protein from sea cucumber polysaccharide
ActiveCN102040667AHigh removal rateHigh retention rateNervous disorderMetabolism disorderMicroorganismUltrafiltration
The invention relates to a method for biologically removing protein from sea cucumber polysaccharide. The method is characterized by comprising the following steps of: inoculating a microorganism into a sea cucumber polysaccharide-containing liquid culture medium; after culturing, removing bacteria from obtained bacterium culture liquid; collecting supernate of the bacterium culture liquid; performing ultrafiltration on the supernate; and drying obtained trapped fluid so as to obtain a protein-removed product of the sea cucumber polysaccharide. The sea cucumber polysaccharide is the mixture of a sea cucumber polysaccharide crude extract, sea cucumber chondroitin sulfate, sea cucumber fucosan dextran sulfate, sea cucumber chondroitin sulfate and sea cucumber fucosan dextran sulfate. Compared with other conventional protein removing methods, the method has the advantages of effectively removing the protein without influencing the original structure of polysaccharide and keeping the polysaccharide well.
Owner:OCEAN UNIV OF CHINA
Process for producing and purifying factor VIII and its derivatives
ActiveUS9441030B2Reducing and blocking its activityImprove homogeneityFactor VIIPeptide preparation methodsProtein targetCultured cell
Disclosed is a method for producing proteins having factor VIII procoagulant activity in serum-free medium by in vitro culturing of mammalian cells, wherein the serum-free medium contains an inhibitor against the protease released from cultured cells. In accordance with this invention, the inhibitor can protect the cleavage of a target protein during cultivation and increase homogeneity of a target molecule, wherein the inhibitor can be a dextran sulfate. This invention also relates to a method of purifying target molecules from the culture medium containing both a target molecule and selected inhibitors by affinity chromatography.
Owner:SK BIOSCI CO LTD
Preparation method of guanidinated chitosan and application of guanidinated chitosan
ActiveCN106905443AImprove the grafting rate of guanidinylationLow toxicityBiocideFungicidesSolubilityMicrosphere
The invention provides a preparation method of guanidinated chitosan. By guanidination modification for chitosan, the biological alkalinity and the water solubility of the chitosan are improved, and the action capacity of the chitosan to an electronegative cell membrane is enhanced; the provided preparation method of the guanidinated chitosan aims to increase the grafting rate of chitosan guanidination and avoid side reaction. The invention further provides a method for preparing antibacterial nano microspheres from the guanidinated chitosan. The method comprises the steps of by taking dextran sulfate as a crosslinking agent, preparing the lysozyme-coated guanidinated chitosan nano microspheres; by the use of the puncture action of the guanidinated chitosan to the cell membrane, the stability of the outer membrane lipid structure of gram negative bacteria (G-) is destroyed to expose peptidoglycan on the inner wall layer, and the peptidoglycan is hydrolyzed through lysozyme; under the synergistic action of the guanidinated chitosan and the lysozyme-coated guanidinated chitosan nano microspheres, the inhibition effect on G- is enhanced.
Owner:JIANGSU ACADEMY OF AGRICULTURAL SCIENCES
Serum-free mammalian cell culture medium, and uses thereof
InactiveUS20090280533A1Improve expression levelIncrease productionCulture processCell culture mediaMammalCell culture media
The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and / or increasing virus production in cultured cells.
Owner:LIFE TECH CORP +1
Method for preparing autologous hematopoietic stem cells, kit, the stem cells and application
ActiveCN104419660AYield advantagePurity advantageAntinoxious agentsDead animal preservationInterleukin 6Culture fluid
Owner:深圳百年干细胞技术研究院有限公司
Method for separating enantiomers of rotigotine and trihexyphenidyl
InactiveCN101544629ARich chiral centerReach flipMaterial analysis by electric/magnetic meansOptically-active compound separationCapillary electrophoresisEnantiomer
The invention provides a method for separating enantiomers of rotigotine and trihexyphenidyl. The method comprises the steps of dissolving dextran sulfate in a buffer solution, obtaining an operational buffer solution containing the dextran sulfate as a chiral selector, dissolving rotigotine to be separated and trihexyphenidyl as samples to be separated in the operational buffer solution and separating enantiomers of two medicaments through a capillary electrophoresis instrument. The method is characterized in that the adopted chiral selector is the dextran sulfate of which the molecular weight is 500,000 or 1,000,000, and is low in background ultraviolet absorption, cheap and readily available. The adopted method has the advantages of high separation efficiency, low reagent consumption, environment-friendly property, convenient operation, capability of realizing the chiral separation of the enantiomers in a forward or backward voltage mode, as well as opposite transfer order of the enantiomers in two modes. The method is high in the degree of separating the enantiomers of the two medicaments.
Owner:BEIJING UNIV OF CHEM TECH
Microfluidic system and coating method therefor
InactiveUS8961901B2Faster filling timeResists contaminationVacuum evaporation coatingPretreated surfacesALLYL SUCROSEBody fluid
Owner:ROCHE DIABETES CARE INC
Coated medical devices comprising a water-insoluble therapeutic agent and an additive
A medical device includes an implantable structure and a coating layer including a water-insoluble therapeutic agent and one or more additives selected from heparin, heparan sulfate, dextran and dextran sulfate, and physiologically-acceptable salts thereof. The one or more additives can be present in an amount effective to increase the rate of release of the water-insoluble therapeutic agent from the coating layer. The implantable medical device structure can be an expandable structure such as a balloon or stent. Also described are methods of making and using such implantable medical devices and coating layers.
Owner:COOK MEDICAL TECH LLC
Adsorbent for extracorporeal blood circulation to remove LDL, preparation method thereof, and perfusion device
ActiveCN109248668AEnsure safetyImprove bindingOther chemical processesSuction devicesSpecific adsorptionExtracorporeal circulation
The invention relates to an adsorbent for extracorporeal blood circulation to remove LDL, a preparation method thereof, and a perfusion device. The adsorbent is formed by introducing an amino group toa carrier and reacting the amino group with a polyanion; and the polyanion is at least one of polyacrylic acid, carbomer and dextran sulfate, wherein the polyacrylic acid is a polyacrylic acid havinga molecular weight of 5,000 to 450,000, or the polyacrylic acid is a mixture of at least two polyacrylic acids with different molecular weights; the carbomer is carbomer with a single grade, or the carbomer is a mixture of at least two carbomers with different grades; and the dextran sulfate is subjected to an hydroformylation reaction together with periodate prior before reacting with the aminogroup, and is subjected to a reduction reaction after reacting with the amino group. The adsorbent has a high adsorption rate and specific adsorption to the LDL.
Owner:JAFRON BIOMEDICAL
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com